Dysphagia in Dystonia by Camargo, Carlos Henrique Ferreira et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Dysphagia in Dystonia
Carlos Henrique Ferreira Camargo, Edna Márcia da Silva Abdulmassih,
Rosane Sampaio Santos and Hélio Afonso Ghizoni Teive
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/60765
1. Introduction
The word dystonia comes from the modern Latin dys- and the Greek tonos [1,2]. It is defined as
a state of disordered tonicity, especially of muscle tissue. The word tone itself has musical
connotations. It derives from the thirteeth-century old French ton, of the voice. The Latin word
tonus meant a stretching, quality of sound, tone, or accent and in turn is derived from the Greek
tonos, similarly translated as stretching, tension and raising of the voice and pitch. In modern
usage, the word dystonic is applied to abnormal tension resulting in abnormal postures present
in many disorders [2]. The definition of dystonia was recently revisited. In 2013, an interna‐
tional consensus committee proposed the following revised definition: Dystonia is a movement
disorder characterized by sustained or intermittent muscle contractions causing abnormal, often
repetitive, movements, postures, or both. Dystonic movements are typically patterned, twisting, and
may be tremulous. Dystonia is often initiated or worsened by voluntary action and associated with
overflow muscle activation [3].
The condition affects most voluntary muscles and is known as cervical dystonia (CD) when
the neck muscles are affected. The term spasmodic torticollis was previously used for this
syndrome, but it does not stress the dystonic nature of the disease [4]. Oromandibular dystonia
(OMD) spasms of the masticatory, facial and lingual muscles result in repetitive and sometimes
sustained jaw opening, closure, deviation or any combination of these, as well as abnormal
tongue movements [5].
Various studies have shown that before treatment is started, some focal craniocervical
dystonias such as spasmodic dysphonia and CD can be accompanied by a range of swallowing
difficulties [6-15]. The incidence of dysphagia varies between 22 and 100 % of CD patients and
is usually over 50 %. It increases significantly after botulinum toxin (BoNT) injection [8,11,12].
Dysphagia is suspected in 36 % of patients with CD on the basis of clinical assessment, and
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the incidence increases to 72 % on electrophysiological evaluation of oropharyngeal swallow‐
ing and after selective rhizotomy [8,9]. Similarly, dysphagia in patients with spasmodic
dysphonia has been reported before and after treatment of this condition [13-15]. Because of
the anatomical distribution of the affected muscles, OMD and co-existing oral-buccal-lingual
(OBL) dyskinesias are associated with abnormal perioral, oral and lingual movements that can
interfere with tasks such as chewing, swallowing and speaking, leading to social embarrass‐
ment and even eating disorders and weight loss. Eating dysfunction has been reported in 15.6
% of OMD cases [16]. Pharyngeal OMD often affects the pharyngeal constrictor muscles and
can occur with spasmodic dysphonia. Choking and difficulty in swallowing are common
complaints. After treatment of spasmodic dysphonia, there may be an unexpected improve‐
ment in pharyngeal dystonia. Treatment for pharyngeal constriction muscle dysfunction is
nearly always associated with dysphagia [17].
Although new radiologic changes were observed in 50 % of CD patients following BoNT-A
treatment, clinically only 33 % of the patients reported new dysphagia symptoms. The severity
of the new dysphagia symptoms correlated strongly with the severity of new radiologic
pharyngeal abnormalities [8].
In this chapter the role of dysphagia as a clinical symptom of cranio-cervical dystonia is
discussed and the occurrence of dysphagia as a common adverse effect of treatment for
dystonias is described.
2. Classification of dystonias
If defining dystonia is difficult and controversial, classifying the various forms of dystonias is
a much more complex task, primarily because the term dystonia can mean not only a disease
but also a symptom that can be part of many disorders with a wide range of causes. In an
attempt to clarify the term, three “surnames” for dystonia were proposed: “symptom”,
“movement” and “disorder”. A patient may complain of dystonia if, for example, he has a
twisted neck. The patient has a dystonia symptom (dystoniaSx). On examination, the signs of
dystonia may be confirmed. This patient then has a dystonia movement (dystoniaMov). Finally,
dystonia as a disorder (dystoniaDx) requires a clinicopathologic understanding of the etiology
of the disease, i.e., whether it is genetic, late-onset, post-traumatic, or has other etiologies [18].
These new definitions led to the replacement of the 1998 dystonia classification [3] by a new
one in 2013. The dystonias are now subdivided according to whether they are the result of
pathological changes or structural damage, have acquired causes or are hereditary. If there is
no clearly defined etiology, the dystonia can be classified as idiopathic familial or idiopathic
sporadic [3].
Recent years have seen significant progress being made in our understanding of the genetics
of dystonias as new loci and genes have been identified. For generalized dystonias, the genetic
mechanisms are better understood, while for focal dystonias, the genes and genetic suscepti‐
bility to the disorder are not yet well identified. Hereditary dystonias (dystoniaDx) are clinically
and genetically heterogeneous. The known genetic forms include all monogenic inheritance
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patterns (autosomal recessive, autosomal dominant, and X-linked). Table 1 shows the heredi‐
tary dystonias grouped according to their similarities. They are divided according to their
clinical features (axis I) and etiology (axis II) in line with the new 2013 classification.
3. Phenomenology and clinical features of cranio-cervical dystonias
3.1. Blepharospasm
Blepharospasm (BSP) is a form of focal dystonia characterized clinically by involuntary
periocular spasms resulting in forceful eye closure [20,21,22]. BSP is characterized by tonic,
phasic or combined involuntary tonic-phasic contractions of the orbicularis oculi muscles,
producing repeated and frequent blinking and persistent forceful closure of the eyelids with
various degrees of functional blindness. The characteristic features of BSP include sensory
tricks that patients use to relieve their symptoms (geste antagoniste) and a high frequency of
ocular symptoms starting before or at the onset of the spasm [20,21,22]. BSP may be associated
with inhibition of the levator palpebrae muscle (apraxia of eyelid opening) or involuntary
movements in the lower face or jaw muscles [20,21,22]. Apraxia of eyelid opening may in turn
be associated with other neurological conditions, such as progressive supranuclear palsy and
corticobasal degeneration [21,22].
3.2. Oromandibular dystonia
OMD refers to involuntary spasms of masticatory, lingual, and pharyngeal muscles that result
in jaw closing (JC), jaw opening (JO), jaw deviation (JD), or a combination of these abnormal
movements [22,23]. When OMD is associated with blepharospasm, the combination is referred
to as “cranial dystonia” or, less appropriately, as “Meige’s syndrome” [24]. Because of the
anatomical distribution of the affected muscles, OMD and co-existing OBL dyskinesias are
associated with abnormal perioral, oral and lingual movements that can interfere with
chewing, swallowing and speaking, leading to social embarrassment [25] and even eating
disorders and weight loss [26]. Examination may reveal a variety of antagonistic maneuvers,
or sensory tricks, including touching the lips or chin, chewing gum, or biting on a toothpick
[21]. Even using these sensory tricks, patients often feel socially embarrassed by the spasms,
which give them a disfigured appearance [22].
3.3. Lingual dystonia
Dystonic involvement of the tongue is a well-recognized feature of tardive dystonia as well as
OMD, both primary and secondary, although primary focal lingual dystonia (PFLD) has only
rarely been described. PFLD presents as an action dystonia during speech or in paroxysmal
episodic lingual dystonic spasms [27]. A rare disorder, it can be severe enough to affect speech,
swallowing and breathing. Tardive lingual dystonia secondary to dopamine-receptor-
blocking drugs may manifest as a relatively isolated problem. Although severe tongue
protrusion, particularly during eating, is characteristic of neuroacanthocytosis, it can also be
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seen in other rare forms of symptomatic dystonias such as pantothenate kinase-associated
neurodegeneration and Lesch–Nyhan syndrome [21].
3.4. Laryngeal dystonia
Laryngeal dystonia (spasmodic dysphonia) is a neurological voice disorder with low preva‐
lence. It is characterized by involuntary adductor (toward the midline) or abductor (away from
the midline) vocal fold spasms during phonation that cause phonatory breaks [20,22]. Some
patients also present with a mixed type of this disorder. Onset of laryngeal dystonia frequently
occurs late in life and presents in mild to severely disabling forms that lead to long-lasting
impaired verbal communication. Adductor spasmodic dysphonia (SD) is undoubtedly the
most common form [22]. Both forms rarely occur in the same individual. Around one-third of
SD sufferers also present with voice tremor, which makes the pitch and loudness of the voice
waver at 5 Hz during vowels and is most apparent when the sound “/a/” (as in “all”) is
produced for at least 5 s [28].
3.5. Cervical dystonia
CD is characterized by involuntary posturing of the head as a result of involuntary spasms,
jerks, or tremors (or a combination of all three) and is often associated with neck pain. Clinical
classification is based on the position of the head and type of movement. The most common
form is rotational torticollis (>50 %). Other relatively frequent forms include laterocollis and
retrocollis, while anterocollis and complex forms of CD (in which there is no predominant
component) are less common. Patients frequently present with a combination of abnormal
patterns, even when it is possible to identify a predominant component [29]. A number of
sensory tricks, including touching the contralateral side of the face as well as ipsilateral to the
direction of head rotation, can produce a temporary improvement in involuntary neck
movements. As with other forms of focal dystonia, the symptoms of CD are exacerbated by
stress and improved by relaxation [20,29].
Clinical category Designation Clinical characteristics Locus Gene Inheritance pattern
Isolated dystonias
Persistent dystonias
Childhood- or
adolescent-onset
dystonias
DYT1 Early-onset primarygeneralized dystonia 9q TOR1-A or DYT1 AD
DYT2 Autosomal recessiveidiopathic dystonia - - AR
DYT6 Mixed dystonia 8p THAP1 or DYT6 AD
DYT13
Early-onset primary
segmental craniocervical
dystonia
1p - AD
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Clinical category Designation Clinical characteristics Locus Gene Inheritance pattern
DYT17
Idiopathic autosomal
recessive primary
dystonia
20pq - AR
Adult-onset
dystonias DYT7
Adult-onset focal
dystonia 18p - AD
DYT21 Late-onset autosomaldominant focal dystonia 2q - AD
DYT23 Adult-onset primarycervical dystonia 9q CIZ1 AD
DYT24 Autosomal dominantcraniocervical dystonia 11p ANO3 AD
DYT25
Late-onset autosomal
dominant primary focal
dystonia
18p GNAL AD
Combined dystonias
Persistent dystonias
Dystonias with
parkinsonism
Without any
evidence of
degeneration
DYT5
Dopa-responsive
dystonia or Segawa
dystonia
14q/1p GCH1 and TH AD and AR
DYT12 Rapid-onset dystoniaparkinsonism 19q ATP1A3 AD
DYT16 Adolescent-onsetdystonia parkinsonism 2p PRKRA or DYT16 AR
With evidence of
degeneration DYT3
X-linked dystonia-
parkinsonism or lubag Xq TAF1 or DYT3 XR
Dystonias with
myoclonus DYT11 Myoclonus-dystonia 7q - AD
DYT15 Myoclonus-dystonia 18p SGCE AD
Dystonias with
chorea DYT4
Dystonia with
whispering dysphonia 19p TUBB4 AD
Paroxysmal dystonias
Paroxysmal
dyskinesias DYT8
Paroxysmal
nonkinesigenic
dyskinesia 1
2q MR-1 AD
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Clinical category Designation Clinical characteristics Locus Gene Inheritance pattern
DYT20
Paroxysmal
nonkinesigenic
dyskinesia 2
2q - AD
DYT10 Paroxysmal kinesigenicdyskinesia 1 16pq PRRT2 AD
DYT19 Paroxysmal kinesigenicdyskinesia 2 16q - AD
DYT18 Exercise-inducedparoxysmal dyskinesia 1p SLC2A1 or GLUT1 AD
*Based on Albanese et al. [3] and Lohmann and Klein [19]
# AD – Autosomal dominant, AR – Autosomal recessive, XR – X-linked recessive
Table 1. The hereditary dystonias *
4. Treatment of craniocervical dystonias with BoNT
While BoNT treatment remains the treatment of preference for most focal dystonias, pharma‐
cological and neurosurgical treatments are also important in the treatment algorithm. Treat‐
ment with BoNT in properly adjusted doses is known to be effective and safe for cranial and
cervical dystonia, but not OMD. In recent years, long-term studies on the efficacy and safety
of BoNT-A have been published, a new BoNT-A formulation has been marketed and new
studies on BoNT-B have been carried out [30]. Systematic reviews and guidelines recommend
that BoNT injections should be offered as a treatment option for CD (for which it has been
proven to be effective) and can be offered for blepharospasm, focal upper extremity dystonia
and adductor laryngeal dystonia (for which it is probably effective) [30,31].
The first study on the use of BoNT for CD was a single-blind study with 12 patients and used
electromyography guidance and a total maximum BoNT-A dose of 200 U (then called Oculi‐
num®) (Smith-Kettlewell Institute, San Francisco, CA, USA). Improvements lasting 4 to 8
weeks were observed in 92 % of the patients, and 25 % reported transient neck weakness [32].
These early results were confirmed by a double-blind, placebo-controlled crossover study of
21 patients using 100 U of BoNT-A which showed an improvement based on investigator
ratings and patient assessment of CD severity [33]. Since then some 80 studies have evaluated
BoNT in CD. Table 2 shows the main results of some studies. Adverse events included
dysphagia and neck weakness [29, 33-38].
While some forms of dystonia are relatively common, such as adult-onset CD, others are less
frequent, and not all clinicians have enough clinical experience to guide their practice [39].
OMD is a type of focal dystonia that affects the lower facial, masticatory, labial and lingual
musculature. When OMD occurs with blepharospasm, the term cranial dystonia is used.
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Meige’s syndrome, a variant of OMD, is a combination of upper and lower facial motor
dysfunction that includes blepharospasm and OMD [40]. Isolated OMD is relatively rare and
represents only 5 % of all dystonias. However, cranial dystonias (OMD, blepharospasm and
Meige’s syndrome) are the second most frequent dystonias (22 %) [40, 41].
Dystonia is not a stereotyped disorder, and in OMD it has a highly variable presentation.
Consequently, treatment must be individualized to accommodate the patients particular
requirements and symptoms. OMD dystonia can be classified into the following types: JC, JO,
JD, lingual, pharyngeal and mixed [41]. BoNT has become the therapy of choice for OMD, and
its use in JO, JC, and JD OMD has been well documented. Although most of the reported
literature on OMD consists of open studies, all these have reported improvement with BoNT.
In general, JO dystonia is more difficult to treat than JC dystonia [41,42].
Dose (U) Motor Pain improvement
Tsui et al. 198633 100 63 % 87 %
Gelb et al. 198934 50-280 80 % 50 %
Jankovic and Schwartz, 199035 100-300 70.7 % 76.4 %
Greene et al. 199036 30-250 74 % -
Jankovic et al., 199037 209 (average) 90 % 93 %
Kwan et al. 199838 190 70 % -
Camargo et al. 200829 100-280(151.05±52.55) 94.1 % 84.4 %
Table 2. Studies with botulinum toxin A (BOTOX®) for cervical dystonia
5. Diagnosis of dysphagia in dystonias
As it is not easy for patients with CD to notice dysphagia, this condition is very often under‐
diagnosed [6,29].
Oropharyngeal function is usually investigated with the aid of videofluoroscopy. Clinical and
videofluoroscopic evaluations have also indicated a high incidence of swallowing disorders
in patients with CD before any treatment such as BoNT injection or rhizotomy [7-9]. In one
study, swallowing abnormalities during video fluoroscopic examination were observed in
over 50 % of CD patients [7].
In general, videofluoroscopic studies of CD patients show delayed initiation of swallowing
and pharyngeal residue [7,10]. CD patients with these signs appear to have “neurogenic
dysphagia” [7,43]. In contrast, asymmetric pharyngeal transit of large liquid boluses is
consistent with tonic or clonic posturing of the head (and pharynx). Although the postural and
neurogenic signs presumably relate to the same underlying neurologic dysfunction and both
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types might be considered “neurogenic,” the authors of some studies suggest that the postural
signs were sufficiently selective and specific to warrant a separate classification [7]. Therefore,
Riski et al. [7] considered the presence of pharyngeal asymmetry with large boluses to be a
sign of “postural dysphagia.” Of 43 patients, 16 showed only neurologic signs; three showed
only postural signs; and three showed combined postural and neurologic signs. The findings
of Riski et al. suggest that swallowing abnormalities in CD are primarily neurogenic but may
be solely postural or combined neurogenic and postural in nature. In agreement with this
conclusion that CD involves neurogenic dysphagia, similar clinical and electrophysiological
findings were reported in patients with OMD and laryngeal dystonia but not CD and in others
with CD. Therefore, dysphagia can occur without abnormal head or neck movements [6].
Electrophysiological abnormalities in dystonic muscles are frequent and are all compatible
with neurogenic dysphagia [6].
Two-thirds of those who complained of dysphagia showed evidence of swallowing abnor‐
malities, and at least one swallowing abnormality was detected radiographically in half of
those who did not complain. This lack of close agreement between subjective reports and
videofluoroscopic results may reflect several factors. Firstly, videofluoroscopic examination
of swallowing can show dysfunctions; however, as the protocol is standardized, it does not
simulate all factors present during meals in the patient’s home, e.g., the full range of textures
and bolus sizes, the speed of bolus presentation and the presence of external distractions.
Secondly, some patients’ concerns with the discomfort or cosmetic disability associated with
their CD may overshadow the relatively subtle abnormalities in oropharyngeal function.
Thirdly, CD patients may have adapted to changes in swallowing function and therefore be
asymptomatic [7].
Dysphagia and dysarthria (which account for 10.2 % to 37 % and 0.9 % of complaints, respec‐
tively) are the two most common adverse effects of BoNT treatment for OMD [37,42]. Clinical
and videofluoroscopic evaluations have also indicated a high incidence of swallowing
disorders in CD patients before any treatment such as BoNT injection or rhizotomy [7-9]. In a
study by Comella et al., although new radiologic changes occurred in 50 % of CD patients
following BoNT treatment, clinically only 33 % of these patients reported new dysphagia
symptoms. The severity of new dysphagia symptoms correlated highly with the severity of
new radiologic pharyngeal abnormalities. This suggests that rather than being routinely
indicated, videofluoroscopic swallowing evaluations should be reserved mainly for patients
with the severest clinical symptoms as an objective measure to assess the possibility of
aspiration [8].
6. Avoiding dysphagia as an adverse effect of treatment for dystonia
Radiologic findings show that in patients with dysphagia prior to treatment with BoNT-A, the
condition did not worsen following treatment [8].
Careful choice of the correct muscle groups with the aid of electromyography before applica‐
tion of BoNT and the use of low dosages may prevent adverse effects [29]. In a study by
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Jankovic et al. [37], in which higher average doses of BoNT were used without electromyog‐
raphy guidance, 24 % of CD patients experienced adverse effects, and of these 23 % suffered
from dysphagia. In a study by Barbosa et al. [43], who used an average dose of 191 U and did
not use electromyography, slightly under half (47 %) of the patients developed dysphagia.
Other factors may have contributed to the low dysphagia indexes found in most studies. For
example, the use of a larger number of injection points in each muscle and application in only
one sternocleidomastoid (thus reducing diffusion of BoNT-A to the pharynx) can reduce the
incidence of dysphagia [29]. Denervation has been shown to occur within a definable area that
crosses anatomic barriers, including fascia and bone. Nevertheless, clinical and laboratory data
suggest that dysphagia secondary to BoNT therapy is the result of toxin spreading from the
sternocleidomastoid injection site to the pharyngeal musculature. Ensuring the injection dose
in the sternomastoid does not exceed 100 IU leads to a substantially reduced incidence of this
complication [12].
7. Conclusion
Dystonia is an important cause of dysphagia. The main aspects to observe in dystonic patients
are:
1. Patients do not normally complain of dysphagia. Comprehensive questioning to confirm
this symptom is therefore essential. When indicated, a search for dysphagia in dystonic
patients should be performed with videofluoroscopy.
2. Optimization of treatment with BoNT (administration of the lowest possible dose, the use
of electromyography and the appropriate choice of muscles) can avoid dysphagia.
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